Mesoblast Ltd traded at 1.92 this Wednesday June 17th, decreasing 0.03 or 1.44 percent since the previous trading session. Looking back, over the last four weeks, Mesoblast lost 5.78 percent. Over the last 12 months, its price rose by 7.37 percent. Looking ahead, we forecast Mesoblast Ltd to be priced at 1.91 by the end of this quarter and at 1.80 in one year, according to Trading Economics global macro models projections and analysts expectations.
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.